查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1965334

即時檢測生物感測器市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、平台、最終用戶、地區和競爭對手分類，2021-2031年

Point-of-care Biosensors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Platforms, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球照護現場生物感測器市場預計將從 2025 年的 815.6 億美元成長到 2031 年的 1,302.2 億美元，複合年成長率為 8.11%。

這些生物感測器是至關重要的分析工具，能夠將生物反應轉化為可測量的訊號，因此無需依賴中心檢查室即可在患者附近進行即時診斷檢測。這種成長主要源於需要定期監測和快速臨床干預的慢性疾病盛行率不斷上升。例如，國際糖尿病聯盟 (IDF) 報告稱，到 2024 年，全球將有約 5.89 億成年人患有糖尿病，這將顯著增加對攜帶式血糖監測設備的需求。此外，醫療服務從醫院轉向居家照護的轉變也進一步加速了這些便利診斷設備的普及。

市場概覽
預測期 2027-2031
市場規模：2025年 815.6億美元
市場規模：2031年 1302.2億美元
複合年成長率：2026-2031年 8.11%
成長最快的細分市場 血糖監測
最大的市場 北美洲

儘管市場前景廣闊，但由於衛生監管機構嚴格而複雜的核准程序，該市場仍面臨許多挑戰。製造商在努力滿足這些嚴格標準的過程中，往往面臨產品開發週期延長和合規成本增加的問題。這些挑戰減緩了新型診斷設備的商業化進程，並阻礙了其在醫療領域的廣泛應用。

市場促進因素

生物感測器與智慧型手機和穿戴式技術的融合正在改變市場格局，實現持續的生理監測和無縫的數據傳輸。這種融合使患者能夠即時監測關鍵生物標記，從而最大限度地減少頻繁就醫的需求，並支持主動健康管理。領先的監測平台表現出色，凸顯了此趨勢的商業性成功。例如，雅培在2024年10月的財報中宣布，其FreeStyle Libre連續血糖監測系統的全球銷售額已達16億美元。這種普及表明，互聯互通和直覺的介面正在推動從零星檢測向長期健康追蹤的轉變，鞏固了這些設備作為現代醫療保健基礎設施重要組成部分的地位。

同時，隨著感染疾病傳播的加劇，全球醫療衛生系統正優先發展快速就地檢驗，以便迅速發現並控制感染。有效的診斷工具對於控制感染疾病和及時啟動治療至關重要，尤其是在檢測設施匱乏的資源匱乏地區。世界衛生組織（世衛組織）發布的《2024年全球結核病報告》顯示，預計2023年全球將有1,080萬人感染結核病，凸顯了便利篩檢方法的迫切需求。為了建構大規模檢測所需的基礎設施，相關產業正在進行大規模的投資和整合。例如，羅氏公司於2023年同意以2.95億美元收購Lumira DX的照護現場平台，以擴展其分散式診斷能力。

市場挑戰

全球照護現場生物感測器市場受到衛生監管機構嚴格而複雜的核准流程的嚴重限制。這些嚴格的標準延長了產品開發週期，迫使製造商應對複雜的合規挑戰，從而延緩了創新診斷工具的上市。因此，企業不得不承擔巨額財務成本，並將大量資源用於行政核准，而非研發。這種資源重新分配減緩了新設備的商業化進程，限制了需要快速檢測解決方案的醫療機構的即時供應，並最終阻礙了整個產業的發展。

此外，這些法規的不確定性影響了策略規劃，並阻礙了製造商在新產品上市時優先考慮特定市場。認證相關的高昂成本和不可預測性正在減緩關鍵技術惠及病患的速度。根據2024年歐洲醫療技術協會（MedTech Europe）的一項調查，與傳統法規結構相比，選擇歐盟作為新醫療設備主要上市區域的主要製造商比例下降了40%。這項數據表明，監管壁壘正在積極阻礙市場成長，並限制先進照護現場生物感測器在全球的應用。

市場趨勢

多重檢測技術的興起，使得同時檢測多種分析物成為可能，並透過單次檢測即可診斷合併症，從而對產業產生了重大影響。這一趨勢在呼吸系統診斷領域尤其明顯，能夠區分 COVID-19、流感和呼吸道合胞病毒 (RSV) 等疾病的症候群特異性檢測組合正在取代單靶點檢測，並有助於改善患者管理。由於醫療機構尋求有效識別症狀重疊的病原體，因此對這些綜合解決方案的需求非常高。丹納赫公司 (Danaher Corporation) 在 2024 年 10 月發布的數據顯示，其採用多重檢測技術的 Cefeed 呼吸系統診斷部門的收入達到 4.25 億美元，這印證了這一轉變，表明同時檢測正成為感染疾病控制的標準做法。

此外，微流體和實驗室晶片技術的應用正在推動市場成長。透過將複雜的檢查室工作流程整合到攜帶式晶片中，可以在臨床環境中進行精確的分子生物學實驗，例如PCR，其速度和準確性可與中心檢查室相媲美。這種小型化也使得在急診診所和私人診所等分散式醫療機構部署高靈敏度診斷工具成為可能。這些平台的商業性成功也反映了這項技術進步。例如，2024年9月，生物梅里埃公司報告稱，其基於微流體的SPOTFIRE系統的銷售額達到3300萬歐元，凸顯了晶片實驗室創新在擴大診斷服務覆蓋範圍方面的重要性。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球即時檢測生物感測器市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品分類（血糖監測、愛滋病毒檢測、C型肝炎檢測、妊娠檢測）
    • 平台特異性（微流體、試紙條、免疫檢測）
    • 依最終使用者（醫院/診所、藥局、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美即時檢測生物感測器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲即時偵測生物感測器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區即時檢測生物感測器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲即時檢測生物感測器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲即時檢測生物感測器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球即時偵測生物感測器市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Abbott Laboratories Inc.
  • Koninklijke Philips NV
  • Accubiotech Co, Ltd.
  • ACON Laboratories, Inc
  • Becton, Dickinson and Company
  • Biolytical Laboratories Inc.
  • Danaher Corporation（HemoCue）
  • Siemens Healthineers AG
  • Meridian Bioscience, Inc
  • GE HealthCare Technologies Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23934

The Global Point-of-care Biosensors Market is projected to expand from USD 81.56 Billion in 2025 to USD 130.22 Billion by 2031, reflecting a CAGR of 8.11%. These biosensors serve as critical analytical tools that translate biological responses into measurable signals, facilitating immediate diagnostic testing near the patient instead of relying on centralized labs. This growth is primarily underpinned by the increasing burden of chronic diseases, which require regular monitoring and swift clinical interventions. For instance, the International Diabetes Federation reported that around 589 million adults worldwide were living with diabetes in 2024, generating significant demand for portable glucose monitoring options. Additionally, the shift of healthcare services from hospital settings to home care environments further accelerates the adoption of these accessible diagnostic devices.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 81.56 Billion
Market Size 2031USD 130.22 Billion
CAGR 2026-20318.11%
Fastest Growing SegmentGlucose Monitoring
Largest MarketNorth America

Despite these growth prospects, the market faces substantial obstacles due to the stringent and intricate regulatory approval procedures mandated by health authorities. Manufacturers frequently grapple with extended product development timelines and escalated compliance costs while adhering to these rigorous standards. Such challenges often postpone the commercialization of novel diagnostic devices and hinder their widespread availability within the healthcare sector.

Market Driver

The convergence of biosensors with smartphones and wearable technology is transforming the market by enabling continuous physiological tracking and seamless data transfer. This integration empowers patients to monitor vital biomarkers in real-time, minimizing the need for frequent hospital visits and supporting proactive health management. The commercial success of this trend is highlighted by the robust performance of major monitoring platforms; for example, Abbott reported in its October 2024 financial results that worldwide sales for the FreeStyle Libre continuous glucose monitoring system hit USD 1.6 billion. This widespread usage demonstrates how connectivity and intuitive interfaces are driving the transition from sporadic testing to long-term health tracking, cementing these devices as essential components of modern medical infrastructure.

Concurrently, the increasing prevalence of infectious diseases is pushing global healthcare systems to emphasize rapid point-of-care testing for immediate detection and outbreak control. Effective diagnostic tools are crucial for managing infections and starting timely treatments, especially in resource-constrained areas with limited laboratory access. The World Health Organization's 'Global Tuberculosis Report 2024' estimated that 10.8 million people fell ill with tuberculosis globally in 2023, underscoring the urgent need for accessible screening methods. To build the necessary infrastructure for such extensive testing, the industry is seeing significant investment and consolidation, such as Roche's 2023 agreement to acquire LumiraDx's point-of-care platform for USD 295 million to broaden its decentralized diagnostic capabilities.

Market Challenge

The expansion of the Global Point-of-care Biosensors Market is significantly impeded by the rigorous and complicated regulatory approval processes enforced by health authorities. These strict standards result in prolonged product development cycles, compelling manufacturers to navigate complex compliance routes that delay the launch of innovative diagnostic tools. As a result, companies endure heavy financial costs and must allocate vital resources toward administrative requirements instead of research and development. This reallocation slows the commercialization of new devices and restricts their immediate availability to healthcare providers needing rapid testing solutions, thereby stalling the sector's overall progress.

Furthermore, this regulatory uncertainty influences strategic planning and deters manufacturers from prioritizing specific markets for new product introductions. The substantial costs and unpredictability linked to securing certifications decrease the pace at which critical technologies reach patients. According to MedTech Europe in 2024, the choice of the European Union as the primary launch region for new medical devices among large manufacturers fell by 40% compared to earlier regulatory frameworks. This statistic demonstrates how regulatory barriers actively hinder market growth and limit the global reach of advanced point-of-care biosensors.

Market Trends

The rise of multiplexing capabilities, which allow for the simultaneous detection of multiple analytes, is significantly influencing the sector by facilitating the diagnosis of co-existing conditions in a single test. This trend is particularly important in respiratory diagnostics, where syndromic panels that distinguish between COVID-19, influenza, and RSV are replacing single-target assays to improve patient management. There is substantial demand for these comprehensive solutions as healthcare providers look for efficiency in identifying pathogens with overlapping symptoms. Highlighting this shift, Danaher Corporation reported in October 2024 that revenue for Cepheid's respiratory diagnostics, utilizing these multiplexed assays, reached USD 425 million, proving that simultaneous detection is becoming a standard practice in infectious disease management.

Additionally, the adoption of microfluidic and lab-on-a-chip technologies is driving market growth by shrinking complex laboratory workflows into portable cartridges. These systems handle minute fluid volumes to execute intricate molecular processes, such as PCR, at the point of care, delivering speed and accuracy similar to central laboratories. This miniaturization enables the deployment of highly sensitive diagnostic tools in decentralized locations like urgent care clinics and physician offices. The commercial success of these platforms reflects this technological evolution; for instance, bioMerieux reported in September 2024 that sales for its microfluidic-based SPOTFIRE system reached EUR 33 million, underscoring the importance of lab-on-a-chip innovations in widening diagnostic access.

Key Market Players

  • Abbott Laboratories Inc.
  • Koninklijke Philips N.V.
  • Accubiotech Co, Ltd.
  • ACON Laboratories, Inc
  • Becton, Dickinson and Company
  • Biolytical Laboratories Inc.
  • Danaher Corporation (HemoCue)
  • Siemens Healthineers AG
  • Meridian Bioscience, Inc
  • GE HealthCare Technologies Inc.

Report Scope

In this report, the Global Point-of-care Biosensors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-of-care Biosensors Market, By Product

  • Glucose Monitoring
  • HIV
  • Hepatitis C
  • Pregnancy

Point-of-care Biosensors Market, By Platforms

  • Microfluidics
  • Dipsticks
  • Immunoassays

Point-of-care Biosensors Market, By End User

  • Hospitals & Clinics
  • Pharmacy
  • Others

Point-of-care Biosensors Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-of-care Biosensors Market.

Available Customizations:

Global Point-of-care Biosensors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-of-care Biosensors Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Glucose Monitoring, HIV, Hepatitis C, Pregnancy)
    • 5.2.2. By Platforms (Microfluidics, Dipsticks, Immunoassays)
    • 5.2.3. By End User (Hospitals & Clinics, Pharmacy, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Point-of-care Biosensors Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Platforms
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Point-of-care Biosensors Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Platforms
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Point-of-care Biosensors Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Platforms
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Point-of-care Biosensors Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Platforms
        • 6.3.3.2.3. By End User

7. Europe Point-of-care Biosensors Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Platforms
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Point-of-care Biosensors Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Platforms
        • 7.3.1.2.3. By End User
    • 7.3.2. France Point-of-care Biosensors Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Platforms
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Point-of-care Biosensors Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Platforms
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Point-of-care Biosensors Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Platforms
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Point-of-care Biosensors Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Platforms
        • 7.3.5.2.3. By End User

8. Asia Pacific Point-of-care Biosensors Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Platforms
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Point-of-care Biosensors Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Platforms
        • 8.3.1.2.3. By End User
    • 8.3.2. India Point-of-care Biosensors Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Platforms
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Point-of-care Biosensors Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Platforms
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Point-of-care Biosensors Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Platforms
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Point-of-care Biosensors Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Platforms
        • 8.3.5.2.3. By End User

9. Middle East & Africa Point-of-care Biosensors Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Platforms
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Point-of-care Biosensors Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Platforms
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Point-of-care Biosensors Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Platforms
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Point-of-care Biosensors Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Platforms
        • 9.3.3.2.3. By End User

10. South America Point-of-care Biosensors Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Platforms
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Point-of-care Biosensors Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Platforms
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Point-of-care Biosensors Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Platforms
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Point-of-care Biosensors Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Platforms
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Point-of-care Biosensors Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abbott Laboratories Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Koninklijke Philips N.V.
  • 15.3. Accubiotech Co, Ltd.
  • 15.4. ACON Laboratories, Inc
  • 15.5. Becton, Dickinson and Company
  • 15.6. Biolytical Laboratories Inc.
  • 15.7. Danaher Corporation (HemoCue)
  • 15.8. Siemens Healthineers AG
  • 15.9. Meridian Bioscience, Inc
  • 15.10. GE HealthCare Technologies Inc.

16. Strategic Recommendations

17. About Us & Disclaimer